Table 2.
Clinical trials of immunotherapy in cutaneous squamous cell carcinoma (revised until 29 January 2020).
| Drug | Treatment | Conditions | Current State | NCT Code |
|---|---|---|---|---|
| Cemiplimab | Alone | Advanced and metastatic CSCC | Completed (47%–50% response rate) Recruiting next phase | NCT02383212 NCT02760498 |
| Alone (before surgery) | Recurrent stage III-IV head and neck CSCC | Recruiting | NCT03565783 | |
| Alone (pre-operative therapy intralesional) |
Recurrent CSCC | Recruiting | NCT03889912 | |
| Adjuvant therapy after surgery and radiotherapy |
High risk CSCC | Recruiting | NCT03969004 | |
| Alone or combination with RP1 |
Advanced or metastatic CSCC | Recruiting | NCT04050436 | |
| Alone | Unresectable locally recurrent and/or metastatic CSCC |
Recruiting | NCT04242173 | |
| Alone (neoadjuvant therapy) | Stage II to IV CSCC | Recruiting | NCT04154943 | |
| Pembrolizumab | Alone | Recurrent/metastatic or locally advanced unresectable CSCC |
Active, not recruiting | NCT03284424 |
| Alone | Locally advanced or metastatic CSCC | Active, not recruiting (preview results presented in ASCO show 42% response rate) |
NCT02883556 | |
| Alone | Locally advanced and metastatic CSCC |
Active, not recruiting | NCT02964559 | |
| Adjuvant therapy after surgery and radiotherapy |
High risk locally advanced CSCC | Recruiting | NCT03833167 | |
| Combination with postoperative radiotherapy |
CSCC of head and neck | Recruiting | NCT03057613 | |
| Combination with cetuximab |
Recurrent/metastatic CSCC |
Recruiting | NCT03082534 | |
| Combination with AST-008 |
Advanced/metastatic CSCC |
Recruiting | NCT03684785 | |
| Combination with abexinostat |
Stage III-IV CSCC of head and neck |
Recruiting | NCT03590054 | |
| Combination with sonidegib |
Stage IV CSCC of head and neck |
Not yet recruiting | NCT04007744 | |
| Combination with nivolumab and CIMAvax vaccine |
Stage III-IV CSCC of head and neck | Recruiting | NCT02955290 | |
| Combination with SO-C101 |
Advanced/metastatic CSCC |
Recruiting | NCT04234113 | |
| Nivolumab | Alone | Locally advanced/metastatic CSCC |
Recruiting | NCT04204837 |
| Alone | Advanced CSCC | Recruiting | NCT03834233 | |
| Alone or combination with ipilimumab | Metastatic CSCC in immunosuppressed patients |
Recruiting | NCT03816332 | |
| Combination with pembrolizumab and CIMAvax vaccine | Stage III-IV CSCC of head and neck | Recruiting | NCT02955290 |